Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company's total debt is $6.60 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2022-12-31 | $6.61 B | -13.01% |
2021-12-31 | $7.60 B | -2.87% |
2020-12-31 | $7.82 B | 22.94% |
2019-12-31 | $6.36 B | 7.26% |
2018-12-31 | $5.93 B | -0.03% |
2017-12-31 | $5.93 B | -8.89% |
2016-12-31 | $6.51 B | -0.14% |
2015-12-31 | $6.52 B | 1015.16% |
2014-12-31 | $0.58 B | -1.79% |
2013-12-31 | $0.59 B | -47.76% |
2012-12-31 | $1.14 B | 7.21% |
2011-12-31 | $1.06 B | -11.59% |
2010-12-31 | $1.20 B | 9.42% |
2009-12-31 | $1.09 B | -1.18% |
2008-12-31 | $1.11 B | -28.78% |
2007-12-31 | $1.56 B | 1516.42% |
2006-12-31 | $96.69 M | 122.57% |
2005-12-31 | $43.44 M | -94.89% |
2004-12-31 | $0.85 B | -4.17% |
2003-12-31 | $0.88 B | 1997.66% |
2002-12-31 | $42.29 M | -48.52% |
2001-12-31 | $82.16 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | $39.65 B | 500.01% | ๐บ๐ธ USA |
![]() Pfizer PFE | $34.87 B | 427.56% | ๐บ๐ธ USA |
![]() AbbVie ABBV | $63.27 B | 857.24% | ๐บ๐ธ USA |
![]() Amgen AMGN | $61.59 B | 831.89% | ๐บ๐ธ USA |
![]() Sanofi SNY | $22.71 B | 243.70% | ๐ซ๐ท France |
![]() Gilead Sciences GILD | $25.23 B | 281.85% | ๐บ๐ธ USA |
![]() Illumina ILMN | $2.98 B | -54.87% | ๐บ๐ธ USA |
![]() Acorda Therapeutics
ACOR | $0.17 B | -97.38% | ๐บ๐ธ USA |
![]() Qiagen QGEN | $1.86 B | -71.84% | ๐ณ๐ฑ Netherlands |
![]() Bio-Rad Laboratories BIO | $1.38 B | -79.00% | ๐บ๐ธ USA |